EC
Therapeutic Areas
Apogee Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Zumilokibart (APG777) | Moderate-to-Severe Atopic Dermatitis | Phase 2 |
| APG279 (Zumilokibart + APG990) | Moderate-to-Severe Atopic Dermatitis | Phase 1 |
| APG273 (Zumilokibart + APG333) | Asthma / COPD | Preclinical |
| APG333 | Respiratory & Broader I&I Conditions | Phase 1 |
| APG808 | Asthma (Type 2 Allergic Diseases) | Phase 1b |
Leadership Team at Apogee Therapeutics
MH
Michael Henderson, MD
Chief Executive Officer
CD
Carl Dambkowski, MD
Chief Medical Officer
JP
Jane Pritchett Henderson
Chief Financial Officer
RD
Rebecca Dabora, PhD
Chief Development Officer
MB
Matt Batters, JD
Chief Legal Officer
JH
Jeff Hartness
Chief Commercial Officer
DM
Dan Mulreany
Chief Business Officer
MC
Mark C. McKenna
Chairman and Chief Executive Officer, Mirador Therapeutics (Board)
LB
Lisa Bollinger, MD
Chief Executive Officer and President of Bollinger Regulatory Consulting (BRC), LLC (Board)
JF
Jennifer Fox
Chief Business Officer & Chief Financial Officer, Zenas BioPharma (Board)